SCHEMBL2118232

SCHEMBL2118232

COc1ccc(S(=O)(=O)Nc2cc(C)cc(-c3sc(C)nc3C)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.51
GABRG2 P18507 1/20 0.51
GABRB3 P28472 1/20 0.51
GABRA3 P34903 1/20 0.51
PKM P14618 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
CYP19A1 P11511 1/20 0.49
SYK P43405 1/20 0.48
PLAU P00749 1/20 0.47
MAPT P10636 2/20 0.47
TP53 P04637 1/20 0.47
ESR1 P03372 1/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
BRD4 O60885 1/20 0.46
PIK3CB P42338 1/20 0.46
NPY5R Q15761 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2118599 0.89 LMNA (0.55) FFAR4PKMALDH1A1HPGDCYP19A1
SCHEMBL2119745 0.80 FFAR4 (0.64) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2118403 0.80 FFAR4 (0.54) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2117686 0.78 FFAR4 (0.61) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2118247 0.75 ALPL (0.54) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2118607 0.75 FFAR4 (0.54) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2120398 0.75 BRD4 (0.64) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2119453 0.74 MEN1 (0.59) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2118624 0.74 FFAR4 (0.53) FFAR4GABRG2GABRB3GABRA3PKM
SCHEMBL2117531 0.74 FFAR4 (0.50) FFAR4GABRG2GABRB3GABRA3PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095024-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1AN, HIF1A, EGLN2 FFAR4 4059/4885GABRG2 4604/4885GABRB3 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.